NIPT DNAHope Signature Panel (aneuploidies of all chromosomes, including trisomies 13, 18, 21, sex chromosome abnormalities, and screening for 20 microdeletion syndromes) with fetal sex determination

About

DNAHope – Signature is a non-invasive genetic panel designed for the early detection of fetal chromosomal abnormalities. The test analyzes fetal cell-free DNA (cfDNA) circulating in the mother's blood plasma and assesses the risk of the most common chromosomal abnormalities: trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Compared to standard screening methods (maternal serum screening, ultrasound), DNAHope – Signature provides more comprehensive and accurate genetic information, without posing any risk to the fetus, unlike invasive procedures such as amniocentesis or chorionic villus sampling. What's included in the DNAHope – Signature panel: Analysis of all 23 chromosome pairs Sex chromosome abnormalities (XO, XXX, XXY, XYY) Fetal sex determination Follow-up testing (karyotyping) if the results indicate high risk Results available within 14 working days Testing can be performed from week 10 to week 30 of pregnancy Screening for 20 microdeletion syndromes